Development and evaluation emulgel for effective management of the imiquimod-induced psoriasis

Inflammopharmacology. 2023 Feb;31(1):301-320. doi: 10.1007/s10787-022-01131-7. Epub 2023 Jan 7.

Abstract

Our main aim is in the present investigation, development and evaluation of seabuckthorn oil-based Emulgel formulation for psoriasis therapy. Anti-psoriatic activity of the SeaEmulgel was studied using Imiquimod-induced psoriasis-like inflammation model Balb/c mice and parameters such as PASI score, ear thickness, spleen to body weight index including histological staining studies, enzyme-linked immune sorbent assay (ELISA), skin compliance and safety evaluation of sea buckthorn oil was performed. The globule size and PDI of sea buckthorn oil emulsion were found to be 172.70 ± 1.73 nm and 0.117 ± 0.018, respectively. In-vivo animal studies performed on male Balb/c mice and emulgel showed a reduction in redness, scaling, inflammation in psoriasis-induced mice, which was analysed by PASI scoring, body weight, spleen weight index and ear thickness. The current investigation clearly revealed the better anti-psoriatic activity of SeaEmulgel formulation against imiquimod-induced psoriasis-like skin inflammation Balb/c mice model.

Keywords: Emulgel; Emulsion; Inflammatory; Interleukin; Psoriasis.

MeSH terms

  • Animals
  • Body Weight
  • Disease Models, Animal
  • Imiquimod / adverse effects
  • Inflammation / pathology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Psoriasis*
  • Skin

Substances

  • Imiquimod